NCT00650104 - Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Parkinson Disease

Interventions

DRUG

Ropinirole XL (formerly CR)

Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.

Trial Locations (10)

19013

GSK Investigational Site, Upland

30912

GSK Investigational Site, Augusta

33136

GSK Investigational Site, Miami

33606

GSK Investigational Site, Tampa

66160

GSK Investigational Site, Kansas City

77030

GSK Investigational Site, Houston

85259

GSK Investigational Site, Scottsdale

90033

GSK Investigational Site, Los Angeles

93030

GSK Investigational Site, Oxnard

08818

GSK Investigational Site, Edison